PPARγ and thiazolidinediones, something more than a treatment for diabetes;PPARγ y tiazolidinedionas, algo más que un tratamiento contra la diabetes

Medicina Clinica

Volumn 115, Issue 10, 2000, Pages 392-397

  Medina, Gema ^a,b   Sewter, Ciaran ^a   Vidal Puig, Antonio J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; CELL RECEPTOR; ISOPROTEIN; LIGAND; THIAZOLE DERIVATIVE; TRANSCRIPTION FACTOR; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; THIAZOLIDINE DERIVATIVE;

ARTERIOSCLEROSIS; CELL DIFFERENTIATION; CELL TRANSFORMATION; FEMALE; HUMAN; HYPERTENSION; MALE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; PHYSIOLOGY; REVIEW; ATHEROSCLEROSIS; CANCER; CARCINOGENESIS; CELL PROLIFERATION; DIABETES MELLITUS; OBESITY; PEROXISOME; TRANSCRIPTION REGULATION;

ARTERIOSCLEROSIS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; LIGANDS; MALE; POLYCYSTIC OVARY SYNDROME; PROTEIN ISOFORMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; THIAZOLES; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 0034734478     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(00)71569-7     Document Type: Review

References (87)

1. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)
2. Peroxisome proliferator-activated receptor-gamma: A versatile metabolic regulator
3. Thiazolidinediones-tools for the research of metabolic syndrome X
4. Thiazolidinediones: A new class of antidiabetic drugs
5. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer
6. The PPARs: From orphan receptors to drug discovery
7. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging
8. Differentiation and reversal of malignant changes in colon cancer through PPARgamma
9. Peroxisomes: Simple in function but complex in maintenance
10. Medical significance of peroxisome proliferator-activated receptors
11. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
12. Differential expression of peroxisome proliferator-activated receptors (PPARS): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat
13. Differential activation of adipogenesis by multiple PPAR isoforms
14. Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions
15. The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs)
16. Identification of fatty acid methyl ester as naturally occurring transcriptional regulators of the members of the peroxisome proliferator-activated receptor family
17. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects
18. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta
19. An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissues
20. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors
21. Peroxisome proliferator-activated receptors, orphans with ligands and functions
22. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: Expression in hematopoietic cells and chromosomal mapping
23. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2
24. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: Alternative promoter use and different splicing yield two mPPAR gamma isoforms
25. mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer
26. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor
27. PPAR gamma3 mRNA: A distinct PPARgamma mRNA subtype transcribed from an independent promoter
28. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents
29. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids
30. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin
31. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma
32. Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma
33. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis
34. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
35. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity
36. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation
37. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: Binding and activation correlate with antidiabetic actions in db/db mice
38. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma
39. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma
40. PPAR-gamma: Adipogenic regulator and thiazolidinedione receptor
41. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells
42. Transcriptional activation by peroxisome protiferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen- activated protein kinase site
43. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: Regulation by peroxisome proliferator-activated receptor gamma
44. Expression of peroxisome proliferator activated receptor mRNA in normal and tumorigenic rodent mammary glands
45. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro
46. Rat preputial sebocyte differentiation involves peroxisome proliferator-activated receptors
47. Failure of programmed cell death and differentiation as causes of tumors: Some simple mathematical models
48. Adipogenesis and obesity: Rounding out the big picture
49. PPARgamma induces cell cycle withdrawal: Inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A
50. Terminal differentiation of human breast cancer through PPAR gamma
51. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor
52. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
53. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo
54. Activators of the nuclear receptor PPARgamma enhance colon polyp formation
55. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice
56. Loss-of-function mutations in PPAR gamma associated with human colon cancer
57. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in rat aortic smooth muscle cells
58. Expression of peroxisome proliferator-activated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells
59. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR-gamma
60. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
61. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages
62. Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPAR gamma activation in mononuclear phagocytes in vitro
63. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein
64. The pathogenesis of atherosclerosis: A perspective for the 1990s
65. Atherosclerosis: Basic mechanisms. Oxidation, inflammation, and genetics
66. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
67. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: Correlation with induction of heme oxygenase 1
68. Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells
69. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
70. The unstable atheroma
71. Peroxisome proliferator-activated receptor agonists
72. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators
73. Hypertension and insulin resistance: Role of peroxisome proliferator-activated receptor gamma
74. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells
75. Peroxisome proliferator-activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway
76. Atherosclerotic plaque rupture: Emerging insights and opportunities
77. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension
78. High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome
79. Hyperinsulinemia in polycystic ovary syndrome: Relationship to clinical and hormonal factors
80. Phenotype and genotype in polycystic ovary syndrome
81. Insulin action in the polycystic ovary syndrome
82. Selective insulin resistance in the polycystic ovary syndrome
83. Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar fatty rats and in cultured adipocytes
84. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: Effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats
85. Fatal hepatotoxicity associated with troglitazone
86. Hepatic dysfunction associated with troglitazone
87. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone